A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy
暂无分享,去创建一个
T. Greene | S. Duvall | S. Beddhu | D. Kohan | M. Munger | Xiaorui Chen | Guo Wei | G. Stoddard | Yufeng Huang | Arsalan N. Habib | D. Simmons | R. Filipowicz | Terrence Bjordahl | Bin Wang | A. Roy | Hanadi Farrukh
[1] S. Chatterjee,et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] David W. Johnson,et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] Kai Huang,et al. High Serum Uric Acid and Increased Risk of Type 2 Diabetes: A Systemic Review and Meta-Analysis of Prospective Cohort Studies , 2013, PloS one.
[4] Qifu Li,et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. , 2013, Clinical therapeutics.
[5] B. Afşar,et al. The role of uric acid in the pathogenesis of human cardiovascular disease , 2013, Heart.
[6] M. Chonchol,et al. Uric acid as a target of therapy in CKD. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] M. Kuo,et al. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[8] Xueqing Yu,et al. Clinical Outcome of Hyperuricemia in IgA Nephropathy: A Retrospective Cohort Study and Randomized Controlled Trial , 2011, Kidney and Blood Pressure Research.
[9] Y. Solak,et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[10] C. Lang,et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.
[11] David W. Johnson,et al. Challenges of conducting a trial of uric-acid-lowering therapy in CKD , 2011, Nature Reviews Nephrology.
[12] C. Baylis,et al. Hyperuricemia as a Mediator of the Proinflammatory Endocrine Imbalance in the Adipose Tissue in a Murine Model of the Metabolic Syndrome , 2011, Diabetes.
[13] M. Goicoechea,et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[14] S. Seirafian,et al. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. , 2010, Iranian journal of kidney diseases.
[15] H. Schumacher,et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial , 2010, Arthritis research & therapy.
[16] M. Kanbay,et al. Uric Acid and Hypertension: Cause or Effect? , 2010, Current rheumatology reports.
[17] V. Sharma,et al. Circulating transforming growth factor-β1 levels and the risk for kidney disease in African-Americans , 2009, Kidney international.
[18] B. Rovin,et al. Uric acid and cardiovascular risk. , 2009, The New England journal of medicine.
[19] V. Sharma,et al. Transforming growth factor beta and excess burden of renal disease. , 2009, Transactions of the American Clinical and Climatological Association.
[20] S. Blair,et al. Uric acid and the development of metabolic syndrome in women and men. , 2008, Metabolism: clinical and experimental.
[21] Richard J. Johnson,et al. Effect of Febuxostat on the Progression of Renal Disease in 5/6 Nephrectomy Rats with and without Hyperuricemia , 2008, Nephron Physiology.
[22] T. Remer,et al. Renal net acid excretion and plasma leptin are associated with potentially bioactive free glucocorticoids in healthy lean women. , 2008, The Journal of nutrition.
[23] T. Srinivas,et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. , 2007, Journal of the American Society of Nephrology : JASN.
[24] P. Magni,et al. Leptin:Adiponectin Ratio Is an Independent Predictor of Intima Media Thickness of the Common Carotid Artery , 2007, Stroke.
[25] T. Nakagawa,et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. , 2007, American journal of physiology. Cell physiology.
[26] A. Bosutti,et al. Low fat adiponectin expression is associated with oxidative stress in nondiabetic humans with chronic kidney disease--impact on plasma adiponectin concentration. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.
[27] G. Curhan,et al. Plasma uric acid level and risk for incident hypertension among men. , 2007, Journal of the American Society of Nephrology : JASN.
[28] Takahiko Nakagawa,et al. A causal role for uric acid in fructose-induced metabolic syndrome. , 2006, American journal of physiology. Renal physiology.
[29] S. Eiam‐Ong,et al. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[30] K. Leung,et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[31] H. Schumacher,et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.
[32] K. Wellen,et al. Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.
[33] S. Srinivasan,et al. Childhood Uric Acid Predicts Adult Blood Pressure: The Bogalusa Heart Study , 2005, Hypertension.
[34] D. Schuster,et al. Discrepancies in the regulation of plasma adiponectin and TNF-alpha levels and adipose tissue gene expression in obese African Americans with glucose intolerance: a pilot study using rosiglitazone. , 2005, Ethnicity & disease.
[35] Morihiro Matsuda,et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.
[36] A. Häkkinen,et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.
[37] A. Masala,et al. Urinary transforming growth factor-β1 in various types of nephropathy , 2004 .
[38] O. Wagner,et al. The interleukin-6 G(-174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans. , 2004, Clinical chemistry.
[39] S. Gogg,et al. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects , 2004, Diabetologia.
[40] E. Ford. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. , 2003, Atherosclerosis.
[41] E. Eldrup,et al. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes , 2003, Mechanisms of Ageing and Development.
[42] S. Mudaliar,et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. , 2003, Diabetes.
[43] L. Truong,et al. A role for uric acid in the progression of renal disease. , 2002, Journal of the American Society of Nephrology : JASN.
[44] R. A. Norman,et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. , 2002, Diabetes.
[45] J. Hughes,et al. Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism , 2001, Hypertension.
[46] V. Sharma,et al. Transforming growth factor-β1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage , 2000 .
[47] M. Alderman,et al. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. , 2000, JAMA.
[48] M. Suthanthiran,et al. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[49] D. Jacobs,et al. Ten-year incidence of elevated blood pressure and its predictors: The CARDIA Study , 1999, Journal of Human Hypertension.
[50] J. Nielsen,et al. Plasma malondialdehyde as biomarker for oxidative stress : reference interval and effects of life-style factors , 1996 .
[51] K. Sharma,et al. Increased Renal Production of Transforming Growth Factor-β1 in Patients with Type II Diabetes , 1997, Diabetes.
[52] A. Ueda,et al. Thiobarbituric acid reactive substances are increased in the subcutaneous fat tissue of patients with end-stage renal disease. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[53] H. Simmonds,et al. Allopurinol treatment and its effect on renal function in gout: a controlled study. , 1982, Annals of the rheumatic diseases.